期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

EGFR-TKI与化疗药物在晚期非小细胞肺癌中最佳联合方式的探讨 被引量：9

Promising combinations of EGFR-TKI and chemotherapy in advanced non-small cell lung cancer
暂未订购
导出
摘要 表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)已成为晚期非小细胞肺癌(NSCLC)的治疗药物之一。如何将EGFR-TKI与传统化疗药物合理组合,从而达到更佳的疗效日益受到人们关注。本文拟将目前研究较多的化疗药物与EGFR-TKI的组合进行综述,梳理可能的最佳联合方式。 Epidermal growth factor receptor tyrosine kinase inhibitor（EGFR-TKI） has been one of the most important treat- ments for advanced non-small cell lung cancer（NSCLC）. How to effectively combine EGFR-TKI with traditional chemotherapy, so as to get a better efficacy, has been given an increasing attention. The aim of this review is to introduce some combinations of EGFR-TKI and chemotherapy, try to find the best combination.
作者 寻琛 王琳 边劲
机构地区 解放军八一医院全军肿瘤中心内科 安徽医科大学南京解放军八一医院临床学院
出处 《临床肿瘤学杂志》 CAS 2012年第12期1141-1145,共5页 Chinese Clinical Oncology
关键词 非小细胞肺癌 表皮生长因子受体 酪氨酸激酶抑制剂 化学治疗 联合用药 Non-small cell lung cancer Epidermal growth factor receptor Tyrosine kinase inhibitor Chemotherapy Combined medication
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献31

  • 1Yang JC, Shih JY, Su WC , et al. Afatinib for patients with lungadenocarcinoma and epidermal growth factor receptor mutations(LUX-Lung 2 ) : a phase 2 trial [ J ]. Lancet Oncol, 2012 , 13(5):539 -548.
  • 2Yamamoto N,Katakami N, Atagi S, et al. A phase H trial ofafatinib ( BIBW 2992) in patients ( pts) with advanced non-smallcell lung cancer previously treated with erlotinih ( E) or gefitinib(G) [J]. J Clin Oncol, 2011 ,29(Suppl) : a7524.
  • 3Yang J, Schuler MH, Yamamoto N,et al. LUX-Lung 3: A ran-domized ,open-label,phase 瓜 study of afatinib versus peme-trexed and cisplatin as first-line treatment for patients with ad-vanced adenocarcinoma of the lung harboring EGFR-activatingmutations[ J ]. J Clin Oncol, 2012 ,30( Suppl) :a LBA7500.
  • 4Cheng H, An SJ, Zhang XC, et al. In vitro sequence-dependentsynergism between paclitaxel and gefitinib in human lung cancercell lines[ J]. Cancer Chemother Pharmacol, 2011 , 67(3) :637-646.
  • 5Herbst HS,Prager D,Hermann R,et al. TRIBUTE : a phase IEtrial of erlotinib hydrochloride ( OSI-774) combined with carbopla-tin and paclitaxel chemotherapy in advanced non-small cell lungcancer[J]. J Clin Oncol,2005 ,23(25) :5892 -5899.
  • 6Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combi-nation with gemcitabine and cisplatin in advanced non-small celllung cancer: a phase 瓜 trial-INTACT 1 [ J]. J Clin Oncol,2004,22(5):777 -784.
  • 7Riely GJ, Rizvi NA,Kris MG, et al. Randomized phase II studyof pulse erlotinib before or after carboplatin and paclitaxel in cur-rent or former smokers with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2009,27(2) :264 -270.
  • 8Janne PA, Wang X, Socinski MA, et al. Randomized phase IItrial of erlotinib alone or with carboplatin and paclitaxel in patientswho were never or light former smokers with advanced lung adeno-carcinoma :CALGB 30406 trial [ J ]. J Clin Oncol, 2012, 30(17):2063 -2069.
  • 9Schuler MH, lanchard DP, Yang J, et al. Interim analysis of afa-tinib monotherapy in patients with metastatic NSCLC progressingafter chemotherapy and erlotinib/gefitinib( E/G) in a trial of afa-tinib plus paclitaxel versus investigator’s choice chemotherapy fol-lowing progression on afatinib monotherapy [ J ]. J Clin Oncol,2012,30(Suppl) : a7557.
  • 10Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase HI studyof erlotinib in combination with cisplatin and gemcitabine in ad-vanced non-small cell lung cancer : the tarceva lung cancer investi-gation trial[J]. J Clin Oncol,2007,25(12) :1545 -1552.

同被引文献83

  • 1张天民.单克隆抗体药物的研究进展[J].医药导报,2005,24(6):494-498. 被引量：9
  • 2陈孝平．外科学[M]．北京：人民出版社，2005：58．
  • 3Dempke WC,Suto T,Reck M.Targeted therapies for non-small cell lung oancer[J].Lung Caneer,2010,67(3):257-274.
  • 4Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase Ⅲ trial [J].Lancet,2008,372(9652):1809-1818.
  • 5Fukuoka M,Wu YL,Tbongprasert S,et al.Biomarker analyses and final overall survival results from a phase Ⅲ,randomized,open-label,first-line study of gefitinib versus carboplatinl paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS)[J].J Clin Oncol,2011,29(21):2866-2874.
  • 6Morgillo F,Bareschino MA,Bianco R,et al.Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy [J].Differentiation,2007,75(9):788-799.
  • 7Hanauske AR,Eismann U,Oberschmidt 0,et al.Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells[J].Invest New Drugs,2008,26(3):215-222.
  • 8Graff JR,McNultyAM,Hanna KR,et al.The protein kinase C beta-selective inhibitor,Enzastaurin(LY317615.HCl),suppresses signaling through the AKT pathway,induces apoptosis,and suppresses growth of human colon cancer and glioblastoma xenografts[J].Caneer Res,2005,65(16):7462-7469.
  • 9Morgillo F,Martinelli E,Troiani T,et al.Sequence-dependent,synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin,a protein kinase C beta inhibitor,in non-small cell lung cancer cells [J].Mol Cancer Ther,2008,7(6):1698-1707.
  • 10Han SY,Zhao MB,Zhuang GB,et al.Marsdenia tenacissirna extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells [J].Lung Cancer,2012,75(1):30-37.

引证文献9

二级引证文献39

临床肿瘤学杂志
2012年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部